Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
Retrieved on:
Tuesday, September 5, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Cognition, Communication, MB, Deficit spending, Medicine, Dravet syndrome, Brain, Month, SLC6A1 epileptic encephalopathy, Incidence, European Journal of Paediatric Neurology, Patient, IEC, ASO, CSF, Therapy, OLE, Behavior, Safety, Disease, Pharmaceutical industry, Pediatric nursing
Four posters from the Company’s work in Dravet syndrome are being presented at the International Epilepsy Congress (IEC) 2023, September 2-6, in Dublin, Ireland.
Key Points:
- Four posters from the Company’s work in Dravet syndrome are being presented at the International Epilepsy Congress (IEC) 2023, September 2-6, in Dublin, Ireland.
- Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
- The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease.
- All presentations are available for download on the Stoke Therapeutics website under the Investors & News tab.